Presence of osteoclast precursor cells during ex vivo expansion of bone marrow-derived mesenchymal stem cells for autologous use in cell therapy

Cytotherapy

Volumn 16, Issue 4, 2014, Pages 454-459

  Allers, Carolina ^a   Lasala, Gabriel P ^a   Minguell, José J ^a  

^a TCA Cellular Therapy   (United States)

Author keywords

Cell therapy; Ex vivo expansion; Mesenchymal stem cells; Osteoclast precursor

Indexed keywords

ARTICLE; BONE MARROW BIOPSY; CARDIOVASCULAR DISEASE; CELL ADHESION; CELL COUNT; CELL POPULATION; CELL SEPARATION; CONTROLLED STUDY; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MESENCHYMAL STEM CELL; OSTEOCLAST PRECURSOR CELL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEM CELL; STEM CELL EXPANSION;

CELL THERAPY; EX VIVO EXPANSION; MESENCHYMAL STEM CELLS; OSTEOCLAST PRECURSOR;

ADULT; BONE MARROW CELLS; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL- AND TISSUE-BASED THERAPY; FEMALE; HUMANS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; OSTEOCLASTS;

EID: 84895781673     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2013.08.006     Document Type: Article

References (38)

1. Minguell J.J., Erices A., Conget P. Mesenchymal stem cells. Exp Biol Med (Maywood) 2001, 226:507-520.
2. Le Blanc K., Ringden O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005, 11:321-334.
3. Meirelles Lda S., Fontes A.M., Covas D.T., Caplan A.I. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev 2009, 20:419-427.
4. Minguell J.J., Allers C., Lasala G.P. Mesenchymal stem cells and the treatment of conditions and diseases: the less glittering side of a conspicuous stem cell for basic research. Stem Cells Dev 2013, 22:193-203.
5. Caplan A.I. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol 2007, 213:341-347.
6. Izadpanah R., Kaushal D., Kriedt C., Tsien F., Patel B., Dufour J., et al. Long-term in vitro expansion alters the biology of adult mesenchymal stem cells. Cancer Res 2008, 68:4229-4238.
7. Conget P.A., Minguell J.J. Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells. J Cell Physiol 1999, 181:67-73.
8. Solchaga L.A., Welter J.F., Lennon D.P., Caplan A.I. Generation of pluripotent stem cells and their differentiation to the chondrocytic phenotype. Methods Mol Med 2004, 100:53-68.
9. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
10. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
11. Wang L., Fan J., Thompson L.F., Zhang Y., Shin T., Curiel T.J., et al. CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J Clin Invest 2011, 121:2371-2382.
12. Lasala G.P., Silva J.A., Gardner P.A., Minguell J.J. Combination stem cell therapy for the treatment of severe limb ischemia: safety and efficacy analysis. Angiology 2010, 61:551-556.
13. Lasala G.P., Silva J.A., Kusnick B.A., Minguell J.J. Combination stem cell therapy for the treatment of medically refractory coronary ischemia: a phase I study. Cardiovasc Revasc Med 2011, 12:29-34.
14. Lasala G.P., Silva J.A., Allers C., Minguell J.J. Combination cell therapy for the treatment of acute myocardial infarction. Int J Cardiol 2012, 157:293-294.
15. Lasala G.P., Silva J.A., Minguell J.J. Therapeutic angiogenesis in patients with severe limb ischemia by transplantation of a combination stem cell product. J Thorac Cardiovasc Surg 2012, 144:377-382.
16. Erices A., Conget P., Minguell J.J. Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol 2000, 109:235-242.
17. Flanagan A.M., Massey H.M. Generating human osteoclasts in vitro from bone marrow and peripheral blood. Methods Mol Med 2003, 80:113-128.
18. Vigorita V. Orthopaedic pathology 2000, Lippincott Williams & Wilkins, Philadelphia. 2nd ed.
19. Mbalaviele G., Jaiswal N., Meng A., Cheng L., Van Den Bos C., Thiede M. Human mesenchymal stem cells promote human osteoclast differentiation from CD34+ bone marrow hematopoietic progenitors. Endocrinology 1999, 140:3736-3743.
20. Koshihara Y., Suematsu A., Feng D., Okawara R., Ishibashi H., Yamamoto S. Osteoclastogenic potential of bone marrow cells increases with age in elderly women with fracture. Mech Ageing Dev 2002, 123:1321-1331.
21. Cao J.J., Wronski T.J., Iwaniec U., Phleger L., Kurimoto P., Boudignon B., et al. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse. J Bone Min Res 2005, 20:1659-1668.
22. Kondo T., Hayashi M., Takeshita K., Numaguchi Y., Kobayashi K., Iino S., et al. Smoking cessation rapidly increases circulating progenitor cells in peripheral blood in chronic smokers. Arterioscler Thromb Vasc Biol 2004, 24:1442-1447.
23. Suh K.T., Kim S.W., Roh H.L., Youn M.S., Jung J.S. Decreased osteogenic differentiation of mesenchymal stem cells in alcohol-induced osteonecrosis. Clin Orthop Relat Res 2005, (431):220-225.
24. Matsushita K., Wu Y., Okamoto Y., Pratt R.E., Dzau V.J. Local renin angiotensin expression regulates human mesenchymal stem cell differentiation to adipocytes. Hypertension 2006, 48:1095-1102.
25. Wang Y., Chen X., Zhu W., Zhang H., Hu S., Cong X. Growth inhibition of mesenchymal stem cells by aspirin: involvement of the WNT/beta-catenin signal pathway. Clin Exp Pharmacol Physiol 2006, 33:696-701.
26. Deng L., Hu S., Baydoun A.R., Chen J., Chen X., Cong X. Aspirin induces apoptosis in mesenchymal stem cells requiring Wnt/beta-catenin pathway. Cell Prolif 2009, 42:721-730.
27. Maseneni S., Donzelli M., Taegtmeyer A.B., Brecht K., Krahenbuhl S. Toxicity of clopidogrel and ticlopidine on human myeloid progenitor cells: importance of metabolites. Toxicology 2012, 299:139-145.
28. Connick P., Kolappan M., Crawley C., Webber D.J., Patani R., Michell A.W., et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol 2012, 11:150-156.
29. Karamouzian S., Nematollahi-Mahani S.N., Nakhaee N., Eskandary H. Clinical safety and primary efficacy of bone marrow mesenchymal cell transplantation in subacute spinal cord injured patients. Clin Neurol Neurosurg 2012, 114:935-939.
30. Mazzini L., Mareschi K., Ferrero I., Miglioretti M., Stecco A., Servo S., et al. Mesenchymal stromal cell transplantation in amyotrophic lateral sclerosis: a long-term safety study. Cytotherapy 2012, 14:56-60.
31. ClinicalTrials.gov: ; accessed December 27, 2012. http://www.clinicaltrials.gov.
32. Le Blanc K., Frassoni F., Ball L., Locatelli F., Roelofs H., Lewis I., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
33. Hare J.M., Traverse J.H., Henry T.D., Dib N., Strumpf R.K., Schulman S.P., et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 2009, 54:2277-2286.
34. Conget P., Rodriguez F., Kramer S., Allers C., Simon V., Palisson F., et al. Replenishment of type VII collagen and re-epithelialization of chronically ulcerated skin after intradermal administration of allogeneic mesenchymal stromal cells in two patients with recessive dystrophic epidermolysis bullosa. Cytotherapy 2010, 12:429-431.
35. Xu J., Wang D., Liu D., Fan Z., Zhang H., Liu O., et al. Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjogren syndrome. Blood 2012, 120:3142-3151.
36. Hare J.M., Fishman J.E., Gerstenblith G., DiFede Velazquez D.L., Zambrano J.P., Suncion V.Y., et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 2012, 308:2369-2379.
37. King A. Stem cells. Could it be TIME to abandon BMCs?. Nat Rev Cardiol 2013, 10:8.
38. Traverse J.H., Henry T.D., Pepine C.J., Willerson J.T., Zhao D.X., Ellis S.G., et al. Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. JAMA 2012, 308:2380-2389.